Zoetis Announces Global Launch of Vetscan OptiCell™ at VMX 2025

• New point-of-care hematology analyzer, Vetscan OptiCell™, to launch at VMX in Orlando, January 25-29, 2025.
• The analyzer's innovative combination of viscoelastic focusing (VEF) and artificial intelligence (AI) technology offers clinics time, space and cost savings.
• First installations planned in the USA, Canada, Australia, New Zealand, the United Kingdom, and Ireland, with rollouts to other key markets throughout 2025 and 2026.

PARSIPPANY, N.J. - December 9, 2024 - Zoetis Inc., the world's leading animal health company, will launch its new screenless point-of-care hematology analyzer, Vetscan OptiCell™, to the global market at the Veterinary Meeting & Expo (VMX) in Orlando, Florida, in January. It is the first cartridge-based, artificial intelligence (AI) powered diagnostic tool for veterinary hematology, providing complete blood count (CBC) analysis for accurate insights in minutes.¹

Abhay Nayak, President of Global Diagnostics at Zoetis, said: "Veterinary professionals worldwide face increased pet owner expectations, heightening demand, and greater labor constraints. Vetscan OptiCell transforms hematology to simplify and strengthen the in-clinic diagnostics experience - helping to save money and redistribute valuable time to patient care. Vetscan OptiCell furthers our commitment to bring direct and meaningful value to practices, patients, and pet owners."

The next generation tool features viscoelastic focusing (VEF), a proprietary microfluidic technology which aligns cells in a single layer to enable sharp focus imaging, minimizing errors and enabling veterinarians to identify platelet recognition within a clump.

It is this technology that facilitates Vetscan OptiCell's single-use cartridge-based system, which contains the blood sample, all reagents, and waste. This offers a significant advantage over traditional reagent pack-based technology to ensure ease of use, minimal maintenance and no calibration requirement, and no sample cross-contamination.

Combining expertly trained AI algorithms with VEF technology, hundreds of thousands of cells are counted during every OptiCell sample run, utilizing hundreds of unique parameters for cellular classification, in just minutes.¹

Accuracy and efficiency are "phenomenal"

Mollyann Holland, DVM, DACVIM (SAIM), owner and veterinarian at Holland's Veterinary Referral Hospital in Oklahoma City - and early user of the device - commented: "The accuracy of Vetscan OptiCell is what I love the most. As a specialist, it means I can feel confident with the platelet counts we're getting, especially for cats, which we know are prone to platelet clumping and therefore unreliable readings from most automated machines. With Vetscan OptiCell, we can get an accurate platelet count - it's phenomenal."

Holland added: "It has also had a big impact on workflow. As a business owner, it's great knowing I don't have to tie someone up for at least an hour changing the fluid pack. Vetscan OptiCell is self-contained, freeing my staff to do medicine rather than having to spend all day with a machine."

For a complete hematology picture, CBC results from Vetscan OptiCell can be paired with Vetscan Imagyst^® AI Blood Smear, together with expert support via the ZoetisDx portal, within the Zoetis Virtual Laboratory. Vetscan OptiCell is the second hematology analyzer available to Zoetis customers, alongside Vetscan^® HM5, which will continue to be sold and supported.

The new analyzer will be available to view at VMX, booth 1908, Orange County Convention Center, Orlando, January 25-29, 2025. Available for order in five countries, Vetscan OptiCell will continue rolling out in key global markets throughout 2025 and 2026.

To view the full diagnostics portfolio, visit www.zoetisdiagnostics.com/us

About Zoetis

As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide - from veterinarians and pet owners to livestock farmers and ranchers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; disruptions in our global supply chain; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development, expected timing of product launches; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rate and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

References

1. Data on file, Study No. DHXMZ-US-24-235, Zoetis Inc.

Media Contacts:
Nantaara Jafri
[email protected]

Garnett Keeler Public Relations
+44 (0)20 8647 4467
[email protected]

# # #

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2024 Zoetis Services LLC. All rights reserved. VTS-01581

Public link

Please use the above public link if you want to share this noodl on another website.